SignifyMD

307 posts

SignifyMD banner
SignifyMD

SignifyMD

@SignifyMD

SignifyMD makes expert medical insights accessible and actionable for today’s oncologists and HCPs. #Oncology #Cancer #MedTwitter

Se unió Haziran 2024
529 Siguiendo168 Seguidores
SignifyMD retuiteado
Dr. Bishoy M. Faltas
Dr. Bishoy M. Faltas@FaltasLab·
Very kind words. Thank you, @DrChoueiri. This has been a true team effort, and I am deeply grateful for the outstanding trainees, collaborators, and colleagues I have had the privilege to work with. We are entering a new era in which deeper biology and translational rigor will meaningfully improve outcomes for patients with #BladderCancer. #EAU26 #TeamScience
Toni Choueiri, MD@DrChoueiri

Dr @FaltasLab of @WeillCornell has become one of the foremost translational/basic authorities in bladder cancer —it was wonderful to see his trajectory over the years ! Bravo Bishoy! #EAU26 @WCMDeptofMed

English
0
3
26
2.5K
SignifyMD retuiteado
Tom Powles
Tom Powles@tompowles1·
A fantastic summary of what’s next in bladder cancer # EAU26 by @scocmem 1) VEGF/PD1 bispecifics and RNA vaccines are promising IOs 2) Novel ADCs like IZABREN (HER1&3) and SAC-TMT in RIII trials 3) New FGFR3 specific targeted therapies as personalized triplets (Vepugratinib/EVP) = FORAGER-2 4) TAR-200 vs BCG in MIBC will have a big impact is postive in R3 @urotoday @EUplatinum @Annals_Oncology @OncoAlert @UroDocAsh
Sara Coca Membribes@scocmem

Excited to have presented today at #EAU26 on “New Therapeutic Options in #BladderCancer". 1/5 Personalised triplets in advanced disease are a major step forward but they're only part of the story ⬇️ @UroDocAsh @OncoAlert @urotoday @EUplatinum @IBCG_BladderCA @Uroweb @JoshMeeks

English
4
27
73
8.4K
SignifyMD retuiteado
OncoAlert
OncoAlert@OncoAlert·
COLLEAGUES AT #EAU26 Our friends from @GuardConsortium 🇪🇸Deliver another Great Informational Capsule, this time direct from #GU26 🇺🇸 We are proud to introduce our Colleague @mjuanfi81 Discussing the Presentation of: KEYNOTE-B15/EV 304 The phase 3 KEYNOTE-B15 trial evaluated perioperative enfortumab vedotin plus pembrolizumab versus standard cisplatin-based chemotherapy in 808 patients with muscle-invasive #BladderCancer eligible for cisplatin. The combination reduced recurrence or progression risk by 47% and improved pathologic complete response rates (56% vs 32.5%). Although higher-grade toxicities occurred, results suggest this regimen may improve survival and represent a potential new perioperative standard, warranting further comparative investigation. buff.ly/LIBgTVi @cdanicas @dralvaropinto @drenriquegrande @nachoduranm @DrJaVallejo @abraocantoMD @docjavip @AlvarezMa89031 @DrFelixGuerrero @BerUrologia @AnaPlatabello1 @AlvarezMa89031 @scocmem @OncBrothers @Helena_de_Palma @F_lopez_campos @Dav_Lorente @EurUrolOncol @tompowles1
English
0
10
14
2.5K
SignifyMD retuiteado
Oncology Brothers
Oncology Brothers@OncBrothers·
No clear consensus and practices differ but more and more data is supporting that we should get CNS imaging upfront for metastatic breast cancer! #OncTwitter #bcsm @JaniceTNBCmets @AMJohnston1315 @OncUpdates @OncoAlert @SusanGKomen
Oncology Brothers@OncBrothers

Do you get upfront brain MRI as part of staging in asymptomatic metastatic HER2+ or triple negative breast cancer? #bcsm @drsarahsam @PTarantinoMD @BijoyTelivala @RenoHemonc @dr_yakupergun @hoperugo @VKaklamani @matteolambe @ErikaHamilton9 @Dr_RShatsky @sdent_cardioonc

English
6
7
19
3.6K
SignifyMD retuiteado
OncUpdates
OncUpdates@OncUpdates·
🤔Headed to #ASCO26 📍Mark these can’t miss events on your 🗓️ calendar! @OncBrothers will be LIVE @ASCO on May 30th! 🔥Oncology Board Review w/ @TwoOncDocs on May 28th! 👉Share with your fellows or anyone needing a review for boards! @ASCOTECAG @HemOncFellows #OncTwitter
Oncology Brothers@OncBrothers

Wow… #ASCO26 is in < 3 months! We are moderating 2 satellite 🗣️ and we would love to see you there. 1. Onc Board Review w/ @TwoOncDocs on May 28 (Thursday afternoon) 2. Adv in Onc: 30 minutes 🗣️ each on GI, GU, Lung, & Breast Ca on May 30 (Saturday evening) #OncTwitter

English
0
8
9
1.6K
SignifyMD retuiteado
Karine Tawagi MD
Karine Tawagi MD@DrKarineTawagi·
📣 calling all artists for the @ASCO SEP Digital Edition Cover Art Contest! 🧑‍🎨🎨 The winner of the contest will have their artwork featured on the cover Individuals or groups can submit artwork by April 6, 2026, at 11:59 EST app.smartsheet.com/b/form/019c777… @TwoOncDocs
GIF
English
1
8
18
2.9K
SignifyMD retuiteado
Tom Powles
Tom Powles@tompowles1·
sac-TMT+pembro in 1st line UC shows ⬆️⬆️ efficacy (Fudan Uni 🇨🇳) . It’s a TROP2/TOPO1 ADC but efficacy looks different from SG or D-DXD @scocmem In 1st line UC it has 68% ORR , 1yr PFS & 80% 12 month OS. 60% TRAEs,13% tox discontinuations. This mono and combo requires further exploration. @OncoAlert
Tom Powles tweet mediaTom Powles tweet mediaTom Powles tweet mediaTom Powles tweet media
English
5
43
113
12.6K
SignifyMD retuiteado
Karine Tawagi MD
Karine Tawagi MD@DrKarineTawagi·
Looking forward to hosting #TumorBoardTuesday on March 24 at 7PM CST w/ @PGrivasMDPhD discussing peri-operative therapy in Bladder Cancer including updates from #ASCOGU26 💫 @TwoOncDocs
#TumorBoardTuesday@TumorBoardTues

@JackieAredoMD @riess_md @IntegrityCE @DrSanjayPopat @stephanieplsaw @StephenVLiu @LeXiuning @NarjustFlorezMD @SukiPaddaMD @JoelNealMD @Latinamd @jillfeldman4 @Exon20Group @drgandara @LeciaSequist @marinagarassino @peters_solange #TumorBoardTuesday 😀That was SUCH an interesting case & discussion 🙏thank you so much @riess_md and @JackieAredoMD for the amazing education 🧑‍🏫 And join us on @TumorBoardTues in 2 weeks, March 24, 2026 when we have @PGrivasMDPhD back with @DrKarineTawagi to🗣️bladder cancer‼️

English
1
5
12
983

Descubrir

@ASCO @MikeSerzanMD @KalantriShreyas @DrChoueiri @reichard_chad @shilpaonc @siadaneshmand @MattGalsky